Group 1 - The stock price of Haishike fell by 5.81% to 47.33 CNY per share, with a trading volume of 73.84 million CNY and a turnover rate of 0.31%, resulting in a total market capitalization of 53.006 billion CNY [1] - Haishike Pharmaceutical Group Co., Ltd. was established on August 26, 2005, and went public on January 17, 2012. The company specializes in the research, development, production, and sales of chemical pharmaceuticals [1] - The main revenue composition of Haishike includes: anesthetic products (39.81%), revenue from cooperative products (23.59%), other indications (17.02%), parenteral nutrition (10.32%), antiemetics for tumors (8.15%), and other (supplement) (0.86%) [1] Group 2 - Morgan Fund holds a significant position in Haishike, with the Morgan Healthcare Stock A Fund (001766) owning 538,800 shares, accounting for 6.04% of the fund's net value, making it the seventh-largest holding [2] - The Morgan Healthcare Stock A Fund has a current size of 453 million CNY and has experienced a loss of 2.77% this year, ranking 5253 out of 5562 in its category [2] - The fund manager, Ye Min, has been in charge for 3 years and 193 days, with the best fund return during this period being 48.26% and the worst being 2.38% [2]